Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Lymphoma
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
Related Questions
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
What is your approach to treatment of mantle cell lymphoma in someone with a mutated gene downstream of the BTK receptor, such as mutated CARD11?
How do you approach patient with CLL/SLL limited to the prostate?
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
Do you still recommend consolidative allogeneic stem cell transplants for patients with Richter transformation in CR after frontline treatment in the modern era of therapies?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How would you treat a stage I fully resected double hit DLBCL?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
